Dublin, April 14, 2026 (GLOBE NEWSWIRE)-- The "Vivotif Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. In recent ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced a series of new commercial partnerships and distribution agreements ...

PaxVax CEO Ken Kelley outside the 2015 JP Morgan Healthcare Conference PaxVax's typhoid vaccine, Vivotif, is licensed for sale in 27 countries. But the Redwood, CA-based company is looking to expand ...

GAITHERSBURG, Md., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic ...

PaxVax has secured up to $60 million in new financing and acquired the oral typhoid vaccine Vivotif® from Crucell as well as its manufacturing facility in Thörishaus, Switzerland. Additionally, PaxVax ...

In a two-step scheme, specialty vaccine developer Paxvax Inc. acquired the FDA-approved oral typhoid vaccine Vivotif from Crucell Switzerland AG and financed the deal with $50 million in secured debt ...

Bavarian Nordic A/S announced that it has entered into an agreement with Emergent BioSolutions Inc. (Emergent) to acquire two marketed travel vaccines, Vivotif for the prevention of typhoid fever and ...

Emergent Travel Health will temporarily discontinue the manufacture and distribution of Vaxchora and Vivotif in the US due to a significant reduction in international travel due to the COVID-19 ...

(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities for Vivotif include rising typhoid incidence in endemic areas, growing demand for travel-linked and oral vaccines, expanded pediatric ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced a series of new commercial partnerships and distribution agreements ...